Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the proof of concept of efficacy of ustekinumab in
subjects with Behçet disease, including patients with oral ulcers (STELABEC-1) and patients
with active posterior uveitis or panuveitis (STELABEC-2)